180 Life Sciences Corporate Media Kit

27 Next Generation Therapeutics: Anti-TNFR2 & Anti-IL-33 Inhibitors Proposed mechanism: 1. Myofibroblasts secrete IL-33 2. IL-33 signals through ST2 receptor on mast cells and macrophages 3. Triggers production of TNF 4. TNF drives differentiation and activation of myofibroblasts Putative Therapeutic Interventions 1. Anti-TNF (in Phase 2b/3 trial with approval only from MHRA/CCMO and relevant accredited ethics committees) 2. Anti-IL-33 and/or anti-TNFR2 (next generation) ➢ Double pronged approach, blocking production of TNF and downstream signaling Patents filed for anti-TNFR2 and anti-IL-33 Claims in USA granted for IL-33, others pending Dupuytren’s disease fibrotic nodules comprise myofibroblasts and immune cells (macrophages and mast cells mostly) Source for Diagram: Izadi D et al. Sci. Adv. 2019; 5 : eaay0370 4 December 2019 – supp data 180 Life Sciences Corp. www.180lifesciences.com Q4 2020